by MM360 Staff | Nov 11, 2020 | Featured News, Myeloma News
GlaxoSmithKline plc (GSK) to use its clonoSEQ® Assay to assess minimal residual disease (MRD) in GSK’s portfolio of hematology products. MRD is increasingly used as an endpoint in clinical trials, and clonoSEQ has emerged as the premier test to reliably and accurately...
by MM360 Staff | Nov 4, 2020 | Featured News, Myeloma News
Allogene Therapeutics, announced that it will present data on ALLO-715, an anti-BCMA AlloCAR T therapy at the 62nd Annual Meeting of the American Society of Hematology (ASH), taking place virtually December 5 – 8, 2020. The oral presentation will include data on...
by MM360 Staff | Oct 29, 2020 | Featured News, Myeloma News
Administering radiation therapy to multiple myeloma patients prior to the administration of CAR T cells was found to be safe and undisruptive to CAR T therapy, according to a new study from researchers in the Abramson Cancer Center at the University of Pennsylvania....
by MM360 Staff | Oct 22, 2020 | CME
Broadcast Date: Thursday, Oct 29, 2020 at 2:00 PM Eastern (11:00 AM Pacific) Despite expanding treatment options for relapsed/refractory multiple myeloma (MM), hematology/oncology teams face persistent barriers to the delivery of quality care across MM patient...
by MM360 Staff | Oct 14, 2020 | Featured News, Myeloma News
Cytovia Therapeutics has entered a research and licensing agreement with Inserm, the French National Institute of Health and Medical Research, to develop NK engager bi-specific antibodies and iPSC CAR NK cell therapy targeting CD38, a key marker of multiple myeloma....
